证券代码：002821 证券简称：凯莱英 公告编号：2023-023 凯莱英医药集团（天津）股份有限公司 出席本次说明会的人员有：公司董事长、首席执行官HAO HONG，董事、首席 财务官张达，高级副总裁兼董事会秘书徐向科，独立董事王青松（具体参会人员 以实际出席为准）。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 20日（星期四）15：00前访问 https://ir.p5w.net/zj/，或扫描下方二维码， 进入问题征集专题页面。在信息披露允许的范围内，公司将在本次说明会上对投 资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于2023年3月31 日 披 露 了 2022 年 年 度 报 告 全 文 及 摘 要 ， 相 关 内 容 详 见 巨 潮 资 讯 网 （http ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-over-year growth of 25%[8]. - The company's operating revenue for 2022 reached ¥10,255,325,392.82, representing a 121.08% increase compared to ¥4,638,834,177.53 in 2021[14]. - The net profit attributable to shareholders for 2022 was ¥3,301,635,019.64, a significant increase of 208.77% from ¥1,069,273,577.50 in the previous year[14]. - The basic earnings per share for 2022 was ¥9.02, an increase of 186.35% compared to ¥3.15 in 2021[14]. - The company has set a revenue guidance of 1.8 billion RMB for the next fiscal year, reflecting a growth target of 20%[8]. - The gross margin improved to 45%, up from 40% in the previous year, due to enhanced operational efficiencies[8]. - The company reported a total cash dividend of RMB 1,456,119,192.54, which includes RMB 656,437,642.20 in cash dividends and RMB 799,681,550.34 from other methods such as share repurchase[153]. Research and Development - The R&D investment for new products and technologies reached 200 million RMB, accounting for 13% of total revenue, indicating a strong focus on innovation[8]. - The number of new drug applications submitted to regulatory authorities increased by 30%, reflecting the company's commitment to innovation and development[7]. - The company aims to launch three new innovative drugs in the next fiscal year, with expected sales of over 500 million RMB[7]. - The company has established a world-class R&D platform with over 4,656 scientists and engineers, focusing on continuous production and enzyme engineering technologies, which are critical for maintaining its competitive edge in the CDMO industry[32]. - The company is focused on expanding its clinical research services and aims to enhance the synergy between clinical CRO services and CDMO services[106]. - The company is actively involved in the development of new pharmaceutical technologies and processes, leveraging over 20 years of experience in the industry[136]. Market Expansion and Strategy - The company plans to expand its market presence in Europe and North America, targeting a 15% increase in market share over the next three years[8]. - The company is targeting increased penetration in the Japanese market and aims to achieve greater breakthroughs in the European market through new technologies[102]. - The company aims to deepen relationships with large clients and expand its market presence in Europe and Japan while focusing on cost control and efficiency improvements in 2023[101]. - The company is committed to optimizing management methods to improve R&D efficiency and reduce production costs, with a focus on early project development[103]. - The company is exploring potential acquisitions to enhance its capabilities in biologics, with a budget of 300 million RMB allocated for this purpose[8]. Operational Efficiency - The company aims to reduce production costs and improve efficiency through continuous process optimization during the commercialization phase[25]. - The company has developed a comprehensive operational system that meets the highest global industry standards, ensuring efficient project management and quality control throughout the drug development lifecycle[33]. - The company has implemented a new operational strategy focused on sustainability, aiming to reduce production waste by 40% over the next three years[132]. - The company has established a competitive compensation system to attract and retain high-quality employees, which includes basic salary, performance bonuses, and other benefits[151]. Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operational activities[112]. - The company has a clear performance evaluation and incentive mechanism to enhance work motivation and achieve operational goals[114]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[114]. - The company has established a performance evaluation system for senior management, linking compensation to the achievement of annual performance targets[158]. Environmental Compliance - Kailaiying Pharmaceutical Group strictly adheres to various environmental protection laws and regulations, ensuring compliance in its production operations[165]. - The company has established comprehensive waste treatment facilities, ensuring stable operation in accordance with national and local standards[166]. - The company has implemented new technologies to monitor and control emissions more effectively[175]. - The company has achieved compliance with national environmental standards, significantly reducing emissions of pollutants such as VOCs and COD[180]. Talent Development - The company has established the "Kailaiying Learning Center" to enhance employee training and development, focusing on cultivating elite talents in the CDMO sector[152]. - The company has a dual career development pathway for employees, allowing for both management and technical career advancements[152]. - The company emphasizes a people-oriented approach to human resource management, establishing mechanisms for talent selection, evaluation, and incentives to enhance sustainable development capabilities[108]. Risk Management - The company faces several risks, including the potential withdrawal or large-scale recall of major innovative drugs, operational risks in clinical projects, and risks related to the lifecycle replacement of key innovative drugs[2]. - The company has not reported any significant changes in the feasibility of its projects[92]. - The company did not identify any major risks or issues during its self-inspection of corporate governance and internal controls[164].